Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer

Active surveillance has been proposed as a therapeutic option in selected intermediate risk patients with biopsy grade group 2 prostate cancer. However, its oncologic safety in this setting is debated. Therefo...

Source: BMC Urology - September 30, 2023 Category: Urology & Nephrology Authors: Giorgio Gandaglia, Riccardo Leni, Sophie Plagakis, Armando Stabile, Francesco Montorsi and Alberto Briganti Tags: Comment Source Type: research